Capstone Investment Advisors
TXMD icon

Capstone Investment Advisors’s TherapeuticsMD TXMD Stock Holding History

Capstone Investment Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,016
Closed -$608K – 545
2017
Q4 		$608K Buy
2,016
+16
+0.8% +$4.45K 0.02% 251
2017
Q3 		$529K Hold
2,000
– – 0.02% 308
2017
Q2 		$527K Buy
+2,000
New +$501K 0.01% 410
2016
Q4 		– Sell
-713
Closed -$242K – 1116
2016
Q3 		$242K Buy
+713
New +$260K 0.01% 649

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capstone Investment Advisors's TXMD Position: Q1 2018 in Review

Capstone Investment Advisors sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 2,016 shares — an estimated $608K sold.

Capstone Investment Advisors first reported a position in TXMD in Q3 2016 and held it in 4 quarters. The position peaked at $608K in Q4 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

  • Capstone Investment Advisors reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,016 TherapeuticsMD shares in Q1 2018, an estimated $608K.
  • Capstone Investment Advisors first reported a position in TherapeuticsMD in Q3 2016 and held it in 4 quarters.
  • Capstone Investment Advisors's TherapeuticsMD position peaked at $608K in Q4 2017.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Capstone Investment Advisors's 13F filing for Q1 2018, filed 15 May 2018.